Seravice Tablets 5/20 Milligrams
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceutical Co., Ltd.
MFDS item code 201906589 · Approved 2019.09.20
This product's status changed to Expired on 2024.09.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used to treat patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with either amlodipine or olmesartan medoxomil. It effectively controls hypertension and helps prevent cardiovascular complications.
This medicine is administered as 1 tablet once daily with water, regardless of food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil); however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with decreased effective intravascular volume: For patients who may have decreased effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment (see section 2, Contraindications). ∘Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
The safety and efficacy in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm or death to the fetus and newborn in the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication's active ingredients or similar drugs, pregnant or nursing women, patients with severe liver impairment or aortic stenosis, patients with biliary obstruction, patients undergoing renal dialysis, patients in a state of shock, and certain diabetic patients should not take this medication. Careful observation is necessary for patients who have low fluid or salt levels, as initial hypotensive symptoms may appear upon administration, and special caution is needed for patients with aortic stenosis, as there is a risk of acute hypotension due to vasodilation. Caution is advised when administering this medication to patients with severe heart disease, weak renal function, or liver impairment, and blood pressure and renal function should be monitored frequently. Patients may experience side effects such as dizziness, headache, hypotension, nausea, skin rash, or edema while taking this medication, and if any unusual symptoms develop, they should consult with healthcare professionals. Patients who have abruptly discontinued beta-blockers should take caution as this medication is not a beta-blocker, and discontinuing it suddenly may pose risks. Drug interactions may occur when taken with other medications, so patients, especially those taking potassium-sparing diuretics, potassium supplements, certain analgesics, or lithium, should inform their healthcare professionals. This medication should not be used during pregnancy as a principle, and if planning to become pregnant or if pregnant, must discuss with a healthcare professional. Nursing mothers should consider discontinuing either breastfeeding or this medication if adverse reactions occur in infants while taking this medication. Children under 18 years old are not recommended for use due to inadequate evidence of safety and efficacy. Elderly patients require careful dosage adjustment and observation due to potential renal and liver function decline. In case of overdose, severe hypotension, vasodilation, tachycardia, and other symptoms may occur, and immediate emergency treatment should be sought if symptoms appear. This medication should be stored out of reach of children and kept away from moisture, heat, and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in an airtight container. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius room temperature to preserve the medication's effectiveness for a longer duration.
White round film-coated tablet
30 tablets/PTP [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Hyuntex Pharmaceutical Co., Ltd.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilseong IS Co., Ltd.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.